SCHEMBL2216207

SCHEMBL2216207

NCc1ccc(C(=O)Nc2ccc(Nc3nc(-c4ccc5cc(O)ccc5c4)cc4ccnn34)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLAU P00749 5/20 0.44
PLG P00747 7/20 0.42
PLAT P00750 3/20 0.42
PRSS1 P07477 3/20 0.42
KLKB1 P03952 3/20 0.42
KLK1 P06870 5/20 0.38
F2 P00734 2/20 0.38
TNIK Q9UKE5 1/20 0.37
KIT P10721 1/20 0.37
PDGFRA P16234 1/20 0.37
KLK6 Q92876 4/20 0.37
LOXL2 Q9Y4K0 2/20 0.36
SMYD3 Q9H7B4 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
DEGS1 O15121 2/20 0.35
HDAC1 Q13547 1/20 0.35
TOP2A P11388 1/20 0.35
TOP2B Q02880 1/20 0.35
LOX P28300 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2213866 0.89 PLG (0.47) PLAUPLGPLATPRSS1KLKB1
SCHEMBL2213434 0.88 KLKB1 (0.45) PLAUPLGPLATPRSS1KLKB1
SCHEMBL2213749 0.87 NPC1 (0.44) LOXL2SIRT2HDAC1LOX
SCHEMBL2216428 0.87 ALDH1A1 (0.41) PLAUPLGPLATPRSS1KLKB1
SCHEMBL2211981 0.87 HDAC1 (0.45) PLAUPLGPLATPRSS1KLKB1
SCHEMBL2215216 0.87 PLAU (0.41) PLAUPLGPLATPRSS1KLKB1
SCHEMBL2216054 0.86 PLAU (0.39) PLAUPLGPLATPRSS1KLKB1
SCHEMBL2215297 0.86 PTPN1 (0.45) PLAUPLGPLATPRSS1KLKB1
SCHEMBL2214589 0.86 HDAC1 (0.45) PLAUPLGPLATPRSS1KLKB1
SCHEMBL2212378 0.85 SNCA (0.49) PLAUPLGPLATKLKB1KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 PLAU 4610/4885PLG 4568/4885PLAT 4238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.